Cluster 0: bisphosphonate hypercalcemia denosumab therapy symptomatic osteoporosis use allowed uncontrolled reasons
Cluster 1: breast cancer metastatic inflammatory diagnosis prior patients diagnosed therapy stage
Cluster 2: voluntary written consent informed related performance procedure signed donor research
Cluster 3: mcl anc neutrophil absolute count 500 days initiation performed treatment
Cluster 4: contraception use agree effective study male potential dose childbearing female
Cluster 5: performance oncology group eastern cooperative ecog status score scale ps
Cluster 6: platelet 000 count 100 mm ul 50 transfusion days mm3
Cluster 7: creatinine gault equation cockcroft clearance min ml calculated estimated using
Cluster 8: bilirubin upper normal limit total uln institutional gilbert serum syndrome
Cluster 9: pd anti l1 l2 prior therapy agent received inhibitor treatment
Cluster 10: test pregnancy negative urine serum female childbearing potential 72 hours
Cluster 11: heart york association new class failure nyha congestive iv iii
Cluster 12: 25 marrow bone radiation therapy prior radiotherapy weeks received irradiated
Cluster 13: hiv positive known infection immunodeficiency patients virus human cd4 antiretroviral
Cluster 14: bilateral potential consecutive hysterectomy oophorectomy undergone months ligation tubal childbearing
Cluster 15: fasting glucose mg dl 300 mmol triglycerides cholesterol plasma serum
Cluster 16: cancer skin non melanoma malignancy situ years carcinoma cervix history
Cluster 17: hemoglobin dl transfusion days mmol registration erythropoietin 14 prior dependency
Cluster 18: aspartate ast aminotransferase uln days obtained transaminase registration metastases liver
Cluster 19: sign consent informed able understand written willing document form legal
Cluster 20: nervous central cns metastases brain disease patients treated stable metastasis
Cluster 21: lactation pregnancy breastfeeding test positive current year women time period
Cluster 22: expectancy life 12 weeks greater estimated patients 16 investigator equal
Cluster 23: adhere requirements able schedule rems program visit protocol willing revlimid
Cluster 24: medical illness psychiatric interfere condition conditions uncontrolled study investigator compliance
Cluster 25: half lives shorter whichever investigational prior weeks therapy drug days
Cluster 26: albumin dl serum mg days initiation treatment performed 14 gm
Cluster 27: requiring infection systemic active therapy antibiotic treatment 14 days intravenous
Cluster 28: inability unwillingness comply consent informed tolerate protocol follow procedures lie
Cluster 29: 18 age years older old time males consent females patients
Cluster 30: treatment prior study previous patients received months disease inhibitors patient
Cluster 31: transaminase glutamic serum aminotransferase sgot oxaloacetic aspartate ast uln pyruvic
Cluster 32: bearing child potential pregnancy test women negative pregnant serum female
Cluster 33: liver disease cirrhosis chronic hepatitis function viral active history biliary
Cluster 34: measurable disease evaluable patients lesion non defined cm criteria lesions
Cluster 35: birth control potential use study effective method agree childbearing women
Cluster 36: study pregnant inform suspect immediately agree contraception duration barrier woman
Cluster 37: stem transplant cell allogeneic autologous hematopoietic prior host months graft
Cluster 38: bowel gastrointestinal gi significantly vomiting absorption malabsorption nausea function disease
Cluster 39: hiv immunodeficiency virus human known infection positive history antibodies patients
Cluster 40: cancer bladder superficial carcinoma situ skin years malignancy cell basal
Cluster 41: colony stimulating csf granulocyte factor factors gm macrophage weeks erythropoietin
Cluster 42: surgery major weeks prior study recovered drug dose effects starting
Cluster 43: hcg chorionic gonadotropin beta human test pregnancy negative potential women
Cluster 44: pt anticoagulant intended anticoagulants ptt time range therapeutic thromboplastin partial
Cluster 45: bp mmhg pressure blood hypertension diastolic systolic antihypertensive 90 140
Cluster 46: infection uncontrolled active patients severe ongoing systemic eligible evidence presence
Cluster 47: response criteria recist solid evaluation tumors measurable disease version evaluable
Cluster 48: brain metastases known patients stable treated metastasis symptomatic excluded untreated
Cluster 49: illness social situations compliance intercurrent uncontrolled requirements psychiatric limited pectoris
Cluster 50: ul absolute neutrophil count 500 anc 000 cells 750 lymphocyte
Cluster 51: mg dl creatinine serum years age bilirubin maximum male 13
Cluster 52: composition compounds similar chemical allergic attributed reactions biologic history used
Cluster 53: mm longest measured measurable accurately dimension lesion diameter ct recorded
Cluster 54: therapy chemotherapy immunotherapy cancer biologic hormonal radiation prior concurrent investigational
Cluster 55: therapy prior received patients systemic disease line anti allowed treatment
Cluster 56: steroid therapy immunosuppressive form systemic receiving immunodeficiency diagnosis days dose
Cluster 57: transplant organ allogeneic history solid prior allograft marrow autologous bone
Cluster 58: unwilling unable protocol comply follow requirements study patients consent abide
Cluster 59: donor hla matched unrelated related donors leukocyte antigen drb1 typing
Cluster 60: live vaccine 30 days attenuated received prior dose study vaccination
Cluster 61: tumor biopsy primary cm patients solid biopsies brain evidence accessible
Cluster 62: inhibitor prior treatment kinase therapy received mek parp tyrosine mtor
Cluster 63: aminotransferase alanine alt uln ast aspartate liver metastases times involvement
Cluster 64: mg equivalent prednisone day corticosteroids 10 dose daily steroids systemic
Cluster 65: pregnancy breastfeeding nursing donor current test lactating planning known active
Cluster 66: hemoglobin 10 dl gm transfusion achieve days intervention hgb acceptable
Cluster 67: carcinoma cell squamous basal skin situ malignancy cervix years treated
Cluster 68: inclusion criteria registration meet apply cohort patients phase specific pre
Cluster 69: qt qtc interval corrected msec ms 470 qtcf 450 480
Cluster 70: karnofsky performance 70 status 60 kps score 80 scale lansky
Cluster 71: mpn advanced blasts mds marrow bone 10 biphenotypic tkis assigned
Cluster 72: receiving currently patients eligible treatment agents anti therapy study investigational
Cluster 73: pregnant nursing patients female females patient subjects excluded currently study
Cluster 74: cardiac ventricular fibrillation arrhythmias atrial history arrhythmia block uncontrolled heart
Cluster 75: specific consent informed study procedures prior provide entry signed patient
Cluster 76: strong cyp3a4 inducers inhibitors cytochrome p450 subfamily family cyp3a polypeptide
Cluster 77: advanced locally metastatic unresectable disease histologically cancer confirmed solid recurrent
Cluster 78: informed consent written signed obtained procedures provided study prior given
Cluster 79: hospitalization requiring registration exacerbation precluding respiratory obstructive transmural coagulation months
Cluster 80: creatinine institutional normal 73 clearance levels min ml 60 limits
Cluster 81: trial clinical participation investigational study therapeutic trials days treatment concurrent
Cluster 82: inr normalized international ratio prothrombin pt uln time coagulation warfarin
Cluster 83: cns metastases nervous central patients involvement symptomatic disease stable treated
Cluster 84: platelets mcl 000 initiation 100 days performed treatment 10 14
Cluster 85: neuropathy grade peripheral pain greater higher existing baseline patients examination
Cluster 86: hepatitis reactive qualitative hbsag rna detected hcv ribonucleic surface acid
Cluster 87: interstitial lung disease history pulmonary evidence signs symptoms known fibrosis
Cluster 88: english read speak able speaking understand spanish write ability language
Cluster 89: significant clinically cardiac disease uncontrolled history pulmonary active investigator dysfunction
Cluster 90: growth factor receptor epidermal factors egfr endothelial vegf support prior
Cluster 91: expectancy life months estimated investigator 12 years patients opinion anticipated
Cluster 92: nervous central involvement known metastases lymphoma active metastasis malignancy leukemia
Cluster 93: pregnancy childbearing test negative potential women serum days prior urine
Cluster 94: docetaxel prior treatment chemotherapy cabazitaxel prostate received cancer patients paclitaxel
Cluster 95: fraction ejection left ventricular lvef 50 40 cardiac 45 echocardiogram
Cluster 96: procedure surgical major anticipation prior study course need days weeks
Cluster 97: fraction muga echocardiogram ejection acquisition scan gated left ventricular lvef
Cluster 98: weeks earlier entering administered adverse events recovered agents radiotherapy nitrosoureas
Cluster 99: ovarian peritoneal fallopian tube epithelial cancer primary carcinoma serous recurrent
Cluster 100: bacterial fungal viral infection active uncontrolled infections systemic requiring antibiotics
Cluster 101: places confounds interpret unacceptable abnormalities condition laboratory data participate study
Cluster 102: alkaline phosphatase uln limit normal upper liver alp bone times
Cluster 103: leukemia acute aml promyelocytic myeloid chronic myelogenous plasma remission cell
Cluster 104: heart failure congestive uncontrolled angina unstable myocardial infarction cardiac symptomatic
Cluster 105: chemotherapy prior received cytotoxic patients regimen regimens treatment systemic cancer
Cluster 106: transaminase aminotransferase serum pyruvate glutamate sgpt glutamic oxaloacetic sgot alt
Cluster 107: hgb hemoglobin dl transfusion achieve 10 intervention acceptable days note
Cluster 108: absolute neutrophil mm count 500 anc cells 000 750 mm3
Cluster 109: cancer prostate diagnosis lung cell small prior patients treatment therapy
Cluster 110: autoimmune atopy asthma childhood subjects syndrome systemic vitiligo excluded resolved
Cluster 111: warfarin heparin anticoagulation low weight molecular therapeutic vitamin dose aspirin
Cluster 112: zubrod performance status patients registration days prior step ps 28
Cluster 113: capacity forced predicted dlco carbon monoxide fev1 expiratory volume pulmonary
Cluster 114: cycle day prior weeks days treatment therapy investigational infection signs
Cluster 115: pneumonitis infectious steroids required non current history interstitial evidence active
Cluster 116: feeding breast pregnant women females pregnancy female patients lactating planning
Cluster 117: abuse substance cooperation disorders interfere psychiatric requirements known trial alcohol
Cluster 118: voluntarily understand sign informed consent form assessments procedures conducted related
Cluster 119: autoimmune disease active history requiring suspected systemic vitiligo known hypothyroidism
Cluster 120: hypersensitivity known excipients history reaction pembrolizumab severe components reactions drugs
Cluster 121: coagulopathy diathesis bleeding evidence history anticoagulation significant therapeutic absence disorder
Cluster 122: transplantation organ allogeneic solid prior marrow bone stem cell history
Cluster 123: lactating pregnant women females female patients nursing study excluded subject
Cluster 124: platinum based chemotherapy regimen disease therapy progression line prior received
Cluster 125: standard therapy care advanced refractory solid available patients treatment metastatic
Cluster 126: seizure disorder history patients seizures medication requiring controlled uncontrolled anticonvulsants
Cluster 127: surgery major days prior 28 14 study recovered dose enrollment
Cluster 128: glomerular filtration rate min ml gfr creatinine estimated 73 renal
Cluster 129: trial subject confound best abnormality results interfere participate laboratory duration
Cluster 130: tablets swallow able unable capsules intact patients inability ability subject
Cluster 131: eastern cooperative oncology group ecog performance status ps patients patient
Cluster 132: corticosteroids systemic immunosuppressive inhaled steroids topical prednisone doses treatment use
Cluster 133: hypertension uncontrolled diabetes pulmonary controlled despite medical poorly severe history
Cluster 134: lenalidomide thalidomide prior hypersensitivity pomalidomide therapy treatment bortezomib dexamethasone carfilzomib
Cluster 135: participants study prior treatment therapy received receiving eligible disease research
Cluster 136: weeks prior study therapy treatment chemotherapy dose enrollment received drug
Cluster 137: cll lymphocytic sll leukemia chronic transformation lymphoma iwcll diagnosis richter
Cluster 138: agents investigational receiving patients participants currently concurrent study use subjects
Cluster 139: world organization health diagnosis aml confirmed classification grade criteria histologically
Cluster 140: cns nervous central involvement active metastases known leukemia lymphoma disease
Cluster 141: expecting conceive trial projected screening children father breastfeeding visit 120
Cluster 142: stage iv iii cancer disease ajcc ii melanoma breast nsclc
Cluster 143: adenocarcinoma histologically prostate confirmed cytologically pancreatic pancreas diagnosis metastatic proven
Cluster 144: anticancer therapy investigational treatment prior weeks concurrent therapies agents study
Cluster 145: samples research purposes provide correlative willing blood tissue mandatory willingness
Cluster 146: abdominal perforation gastrointestinal fistula abscess intra history months gi bowel
Cluster 147: study interfere results investigator interpretation participation condition judgment inappropriate patient
Cluster 148: paraffin tissue tumor slides embedded formalin fixed unstained block ffpe
Cluster 149: grade toxicity prior therapy recovered alopecia toxicities related adverse baseline
Cluster 150: demonstrated function adequate liver reserve following organ marrow inadequate bone
Cluster 151: leukocytes 000 mcl ul mm microliter 500 days registration 14
Cluster 152: antiretroviral combination hiv immunodeficiency positive ineligible virus human therapy patients
Cluster 153: ct tomography imaging computed scan mri pet resonance magnetic disease
Cluster 154: her2 receptor er ihc negative positive estrogen breast progesterone fish
Cluster 155: 75 000 platelets platelet count mm ul mcl 10 plt
Cluster 156: exclusion criteria apply registration cohort treatment specific protocol patients inclusion
Cluster 157: nature informed aware consent indicating investigational sign risks study benefits
Cluster 158: surgically childbearing sterile potential abstain heterosexual activity sterilized study methods
Cluster 159: pregnancy test positive lactating female serum screening period women pregnant
Cluster 160: female male pregnant potential subjects childbearing patients breastfeeding participants subject
Cluster 161: organomegaly endocrinopathy polyneuropathy poems changes monoclonal protein syndrome skin plasma
Cluster 162: replacement systemic thyroxine pituitary insulin modifying physiologic adrenal insufficiency therapy
Cluster 163: criteria eligibility meet medi following phase cohort study patients laboratory
Cluster 164: myocardial infarction months angina unstable history prior coronary study acute
Cluster 165: allergy known hypersensitivity components history study excipients formulations drug reaction
Cluster 166: days prior 14 28 study registration dose drug 30 therapy
Cluster 167: adjuvant chemotherapy therapy neoadjuvant prior setting months metastatic neo treatment
Cluster 168: carcinoma skin cell potentially progressing curative basal exceptions undergone additional
Cluster 169: terminology common adverse ctcae events grade criteria version alopecia toxicities
Cluster 170: ul platelets 100 000 10 days plt cells 14 prior
Cluster 171: provide informed consent written ability unable willingness procedures patients understand
Cluster 172: consent informed authorization health written ability information study hipaa provide
Cluster 173: bilirubin total uln mg dl gilbert syndrome direct serum subjects
Cluster 174: pugh child class score hepatic impairment cirrhosis liver severe classification
Cluster 175: organ function adequate defined hematologic end marrow laboratory following values
Cluster 176: ng psa ml testosterone prostate dl 50 serum level rising
Cluster 177: mcl neutrophil absolute 500 count anc 000 microliter 200 days
Cluster 178: neutrophil absolute count 10 anc 109 cells days 000 14
Cluster 179: mri imaging contrast magnetic resonance undergo contraindication patients brain gadolinium
Cluster 180: opinion investigator condition medical study patient compromise subject safety participation
Cluster 181: oral swallow medication retain able medications ability patient patients unable
Cluster 182: radiotherapy prior weeks chemotherapy treatment study palliative received days patients
Cluster 183: meningitis carcinomatous metastases nervous central cns brain known evidence active
Cluster 184: healing wound fracture ulcer non bone presence active untreated 28
Cluster 185: visits comply scheduled able willing tests procedures laboratory treatment study
Cluster 186: ascites pleural effusion effusions pericardial paracentesis requiring drainage clinically significant
Cluster 187: breastfeeding pregnant women females female patients patient subject excluded study
Cluster 188: leptomeningeal disease brain metastases carcinomatosis metastasis cord spinal compression history
Cluster 189: protein light serum chain dl free mg flc abnormal ratio
Cluster 190: histologically confirmed cytologically diagnosis metastatic cancer cell carcinoma patients solid
Cluster 191: creatinine gault cockcroft clearance formula min ml calculated using 50
Cluster 192: planned therapy surgery treatment study radiation chemotherapy weeks current use
Cluster 193: tissue tumor biopsy archival available fresh sample analysis provide availability
Cluster 194: lymph node nodes axillary sentinel cm biopsy dissection disease regional
Cluster 195: able consent provide informed written willing trial assent study patients
Cluster 196: infections active uncontrolled requiring systemic illnesses antibiotics opportunistic severe medical
Cluster 197: diabetes mellitus type uncontrolled controlled a1c insulin poorly hba1c glucose
Cluster 198: thrombosis deep embolism pulmonary vein venous history dvt months arterial
Cluster 199: limits normal institutional bilirubin total upper creatinine uln serum gilbert
Cluster 200: creatinine uln serum institutional times renal days registration cr obtained
Cluster 201: upper normal limit ast alt times bilirubin uln institutional range
Cluster 202: syndrome qt history long myelodysplastic congenital gilbert known family patients
Cluster 203: site staff primary study disease conduct astrazeneca tumor applies biopsy
Cluster 204: greater equal dl grade hemoglobin years cm age patients 10
Cluster 205: myeloma multiple diagnosis relapsed refractory imwg therapy criteria working international
Cluster 206: satisfy criteria following enrolled subjects patient study patients portion enrollment
Cluster 207: patients history disease study patient prior subjects use months known
Cluster 208: function adequate renal hepatic hematologic liver defined hematological coagulation cardiac
Cluster 209: board review irb approved institutional consent informed sign understand written
Cluster 210: autoimmune past years systemic disease active treatment required requiring documented
Cluster 211: methods abstinence ovulation practice contraception agree lifestyle usual periodic true
Cluster 212: infectious pneumonitis non active evidence known history process disease clinical
Cluster 213: women potential contraception childbearing use men effective contraceptive method sexually
Cluster 214: obtained newly tissue biopsy excisional core tumor lesion specimen archival
Cluster 215: hepatitis virus immunodeficiency hiv human infection active known hcv hbv
Cluster 216: willingness understand sign ability written document informed consent subjects subject
Cluster 217: bowel disease inflammatory colitis crohn ulcerative autoimmune history active arthritis
Cluster 218: tb tuberculosis bacillus active known history excluded patients latent patient
Cluster 219: hepatitis active infection known chronic hiv history viral positive patients
Cluster 220: pneumonitis fibrosis idiopathic organizing pneumonia induced pulmonary history chest obliterans
Cluster 221: ecog performance status score ps patients appendix gog scale equal
Cluster 222: tuberculosis active history known previous clinical diagnosis latent infection hepatitis
Cluster 223: creatinine upper normal limit uln serum institutional times age limits
Cluster 224: 1500 neutrophil absolute count anc mm ul cells mm3 10
Cluster 225: weeks earlier monoclonal administered recovered antibody adverse events mab prior
Cluster 226: lansky 16 karnofsky score years 50 age performance patients 60
Cluster 227: care medical consent prejudice withdrawn future understanding voluntary procedure written
Cluster 228: women pregnant nursing excluded study employ unwilling men contraception following
Cluster 229: lipase amylase uln serum pancreatitis normal radiologic upper clinical limit
Cluster 230: invasive breast cancer carcinoma dcis ductal situ diagnosis lobular contralateral
Cluster 231: trc102 mother discontinued breastfeeding excluded treated pregnant women study episode
Cluster 232: swallow capsules pills able inability unable patients tablet ability patient
Cluster 233: time thromboplastin partial ptt prothrombin pt inr uln normalized ratio
Cluster 234: immunodeficiency acquired aids primary known syndrome hiv history virus human
Cluster 235: ischemic attack transient cerebrovascular accident months stroke history myocardial coronary
Cluster 236: hepatitis positive virus hcv antibody antigen hbv surface infection test
Cluster 237: conjugated sum unconjugated bilirubin age upper uln limit normal direct
Cluster 238: creatinine clearance calculated uln crcl place institutional gfr measured glomerular
Cluster 239: platelets 000 50 mcl mm ul 10 cells 80 transfusion
Cluster 240: aminotransferase upper aspartate alanine ast normal alt limit uln times
Cluster 241: condom intercourse drug males father sexually vasectomized stopping taking child
Cluster 242: grapefruit juice seville oranges cyp3a4 fruits inhibitors star fruit study
Cluster 243: stroke hemorrhage intracranial history months enrollment prior accident cerebrovascular cerebral
Cluster 244: protein urine 24 hour ratio proteinuria creatinine dipstick upc mg
Cluster 245: finding metabolic reasonable suspicion contraindicates examination dysfunction physical render giving
Cluster 246: marrow bone function adequate renal liver organ hepatic kidney defined
Cluster 247: bone marrow blasts blood patients peripheral biopsy disease transplant aspirate
Cluster 248: traumatic injury major procedure significant surgical open biopsy days 28
Cluster 249: vaccines live attenuated influenza flu seasonal allowed inactivated intranasal vaccine
Cluster 250: expectancy life greater months weeks equal estimated 12 physician patients
Cluster 251: guidelines informed federal consent accordance institutional written nature sign investigational
Cluster 252: comply study procedures requirements able protocol follow willing inability investigator
Cluster 253: count absolute neutrophil 000 mm3 anc lymphocyte 109 cells mm
Cluster 254: mother breastfeeding discontinued pregnant excluded women treated study agents potential
Cluster 255: cerebrovascular accident transient embolic ischemic attacks thrombotic venous events thrombosis
Cluster 256: hemoglobin dl hb mmol gm mg greater 90 11 weeks
Cluster 257: potassium calcium magnesium serum normal lln lower corrected limits mmol
Cluster 258: signed informed consent form dated patient document guardian study given
Cluster 259: malignancy years active history concurrent treatment prior diagnosed patients treated
Cluster 260: fcbp agree pregnancy contact lenalidomide latex sexual potential childbearing vasectomy
Cluster 261: return follow institution enrolling willing monitoring phase active mayo clinic
Cluster 262: bleeding diathesis active history gastrointestinal significant disorders disorder hemorrhage known
Cluster 263: sensory neuropathy grade motor peripheral ctcae alopecia equal related persisting
Cluster 264: anti pd antibody ctla programmed death l1 cell checkpoint l2
Cluster 265: karnofsky performance eastern cooperative oncology ecog group status 60 70
Cluster 266: pressure hg blood mm systolic diastolic hypertension 90 uncontrolled 140
Cluster 267: mmhg pressure blood systolic diastolic hypertension 90 uncontrolled 150 140
Cluster 268: 1000 neutrophil absolute count anc mm ul support filgrastim days
Cluster 269: male female 18 years age older aged patients subjects consent
Cluster 270: uln alt ast liver transaminase alanine metastases aspartate aminotransferase bilirubin
Cluster 271: effects recovered toxic prior acute therapy fully grade chemotherapy reversible
Cluster 272: absorption gastrointestinal malabsorption gi interfere oral condition disease syndrome medication
Cluster 273: antibiotics infection requiring active intravenous parenteral iv antifungals antivirals systemic
Cluster 274: creatinine clearance min ml calculated 50 serum 60 30 mg
Cluster 275: lymphoma cell hodgkin large follicular diffuse dlbcl refractory mantle non
Cluster 276: interstitial pneumonitis lung disease history infectious evidence active non pulmonary
Cluster 277: cancer treated adequately cell situ skin malignancy years basal squamous
Cluster 278: postmenopausal menopausal hormone women post fsh year follicle bilateral oophorectomy
Cluster 279: transplantation stem cell allogeneic autologous hematopoietic prior patients eligible graft
Cluster 280: contraception methods intrauterine barrier device use method contraceptive potential condom
Cluster 281: brentuximab vedotin prior treatment bv hypersensitivity received previous dose bendamustine
Cluster 282: dose contraception 120 study method adequate male use starting therapy
Cluster 283: disorder psychiatric history bipolar uncontrolled medical schizophrenia major active disease
Cluster 284: nci institute national ctcae grade common terminology cancer adverse events
Cluster 285: platelet count 10 100 109 75 50 transfusion days ul
Cluster 286: transfusions red blood hemoglobin dl rbc cell receive transfusion platelet
Cluster 287: times bilirubin upper normal limit total uln gilbert institutional syndrome
Cluster 288: second malignancy active currently cancers melanoma skin considered cancer years
Cluster 289: radiation therapy prior weeks chemotherapy treatment patients received surgery study
Cluster 290: white wbc blood cell ul cells 000 count 2000 mm
Cluster 291: longer whichever half lives investigational drug days study prior treatment
Cluster 292: platelets 100 000 mcl mm 10 cells days registration plt
Cluster 293: investigational agent study treatment weeks device participated currently drug receiving
Cluster 294: 3000 white wbc blood mm cells cell count ul days
Cluster 295: metastatic disease evidence patients distant recurrent prior chemotherapy unresectable therapy
Cluster 296: cardiovascular significant disease clinically uncontrolled history including pulmonary evidence conditions
Cluster 297: surgical resection patients prior biopsy candidate disease surgery procedure patient
Cluster 298: recist measurable disease v1 version criteria defined lesion according evaluable
Cluster 299: heart york association new myocardial class infarction angina failure cardiac
